FOR HEALTHCARE PROFESSIONALS

D’OXYVA® improves dermal microcirculation and promotes wound healing in the diabetic foot (clinical trial update)
READ ARTICLE
Circularity Healthcare receives Pasadena Award
READ ARTICLE
Circularity Healthcare announces expansion of successful human pivotal trials with global CRO
READ ARTICLE
This one thing makes you twice as likely to die from coronavirus
READ ARTICLE

rapid & real solution FOR YOUR CLIENTS

D'OXYVA® INTENDED USE

D’OXYVA® (deoxyhemoglobin vasodilator) is intended for significant enhancements in the regulation of the autonomic nervous system (ANS) including tissue microcirculation with cellular oxygenation, which is being recognized in a rapidly growing number of published randomized clinical trials leading to a variety of significant clinical outcomes. In short, D’OXYVA has demonstrated outsized improvements in blood circulation, cellular oxygenation, tissue perfusion in the microvessels, micro-, and macro-vascular functions, and neural signal activation in the autonomic nervous system according to randomized human clinical trials.Microcirculation and autonomic nervous system dysfunction is increasingly regarded by the mainstream scientific medical community as the underlying cause of the most widespread health complications for both the young and elderly. Among other things, restrictions in these processes impede normal organ functions, the flow of antibodies, white blood cells and platelets, and rob the skin and body of oxygen and essential nutrients.
SWITCH TO THE ONLY GENTLE, RAPID, EFFECTIVE, AND PAINLESS SOLUTION WITHOUT BREAKING THE BARRIER OF YOUR SKIN!D’OXYVA® promises painless and fully noninvasive and nontoxic delivery of far higher concentrations of medication more directly, more quickly, and with greater efficacy than traditional and competing medication delivery methods. It reduces or eliminates adverse side effects. Competing skin delivery technologies try passing active pharmaceutical ingredients (API) through the skin layers. This often limits the molecular sizes and leads to adverse side effects such as skin irritation or permanent tissue damage.D’OXYVA’s unique skin microcirculation  (skin perfusion pressure) solution uses a high concentration of ultra-purified medical Carbon Dioxide (CO2) and water vapor in a molecular form, sprayed gently on the skin surface. The resulting vapor solution is a so-called supersaturated gas vapor, adjusted to the pH of your skin. Human skin is oily and watery and CO2 readily dissolves in our skin in molecular form with the patented and patent-pending process unique only to D’OXYVA.
D’OXYVA® is a relatively affordable, low-risk, non-invasive, non-toxic, non-opioid, both adjunct and stand-alone solution for the forward-looking health facility and patient wanting to significantly reduce cost of treatment and readmission rates, while improving patient compliance.For example, in controlled human clinical studies with D’OXYVA, severe (Wagner stage II – III) diabetic ulcer wounds typically healed and closed within 4 – 8 weeks with an average 2 applications per day and 125 total, costing about $1,500 at out-of-pocket retail price. In comparison, according to various market research studies such as conducted by the Mayo Clinic, the direct cost to treat such wounds with existing modalities yielding only 15 – 20% success is roughly $6,000 – $20,000 annually in the U.S. (not counting indirect cost estimates that are multiples of direct cost) that affects well over 7 million people in the U.S. alone.

The recommended average starting dose of D’OXYVA® is 16g CO2 twice daily for 5 days per week for the first 2 weeks and once daily for 5 days per week for another 2 weeks. The average maintenance dose of D’OXYVA can be once a day for 3 days per week. The starting and maintenance dose of D’OXYVA should be individualized according to patient characteristics such as goals of therapy and response.

Blood flow (perfusion index), oxygen (SpO2 and TcPO2), blood pressure, blood glucose, heart rate variability, sympathetic/parasympathetic nerve activity, blood pH, and other vitals should be analyzed within 2 to 4 weeks after starting D’OXYVA® and dosage adjusted according to results.Stopping D’OXYVA after only 4 weeks is not recommended and it may not provide the expected long-term benefits even if major benefits and clinical outcomes were realized!D’OXYVA is becoming exceptionally advantageous for the patient, health care practitioner, and the entire healthcare system, and is starting to provide substantial cost savings and improvements in quality of life for a wide variety of health complications for people of all ages and backgrounds.

IMPORTANT SAFETY NOTICE: According to various human clinical trials with D’OXYVA, this product does NOT increase blood (PCO2) or tissue (TcPCO2) Carbon Dioxide (CO2) levels like anesthesia or other inhalation, needle injection or skin delivery CO2 medical gas delivery applications. It DOES improve blood (SpO2) and tissue (TcPO2) oxygen and pH balance. Increased CO2 levels in blood and tissue may be detrimental to some but increased O2 levels are typically beneficial.

D’OXYVA® (deoxyhemoglobin vasodilator) is becoming a standard setter in numerous fields and the first choice of doctors in a growing number of countries around the world for the solution of the most difficult complications caused by chronic diseases such as diabetes, cardiovascular, and various forms of cancer such as multiple myeloma.

FEATURED

Expert Interviews

Dr. Geoffrey Watson
Dr. Geoffrey Watson
Watson Wellness Center in Oakland, CA
"D’OXYVA has shown significant promise for severe cases of diabetic foot ulcers. Its therapeutic effects have circulatory and neurological benefits as well."
Dr. Michael McGlamry
Dr. Michael McGlamry
Forsyth Foot and Ankle Associates, Cumming, GA
"D’OXYVA demonstrated hastened wound improvement and eventual wound closure in an average of 5 weeks**."
Dr. Felix Sigal
Dr. Felix Sigal
Foot and Ankle Clinic, Los Angeles Podiatrist
"D'OXYVA has the potential to prevent symmetrical peripheral gangrene, a limb-threatening complication of COVID-19."
Previous
Next
doxyva applicator cross section

D’OXYVA® (deoxyhemoglobin vasodilator) is the only fully non-invasive, non-irritating, non-opioid, and completely painless, skin delivery (over-the-skin) nerve stimulant and microcirculatory solution.

With over seven years of industry-leading research results, D’OXYVA® demonstrated that it does not break the skin’s barrier while it provides outsized quality of life and outcomes quickly and affordably.

In short, based on current leading neurology, immunology, microvascular, and cellular oxygenation science, D’OXYVA® is leading the field by:

✓ Significantly lowering the risk of diabetes and cardiovascular complications.

✓ Providing complete significant improvement of difficult wounds together with major pain relief and improved quality of life.

D’OXYVA®‘s gentle vapor solution with purified CO2 readily dissolves in a molecular form in the skin, acting as a catalyst to improve skin perfusion pressure and optimize nerve functions and microcirculation.

D’OXYVA® delivers fast solution to the areas you need it most. It’s also easy-to-use virtually anywhere — even from the comfort and privacy of your own home.

physician-recommended,
easy to use daily

How D'OXYVA Works?

For example, D’OXYVA® naturally delivers remarkable and fast pain management results without the use of opioids. In high-quality studies, it has demonstrated noticeable efficacy in the reduction and elimination of chronic pain — achieving over 90% elimination of all varieties of chronic pain in nearly all enrolled subjects the same day or in a few days.

D’OXYVA® (deoxyhemoglobin vasodilator) is a handheld applicator that’s the first biotech solution of its kind, underpinned by widely established, groundbreaking, Nobel Prize–winning science.

It’s been studied to significantly improve macro-, and micro-circulation of blood flow and certain nerve activities in the body, which is widely reported to boost fitness and form an effective noninvasive, pain-free solution for several widespread conditions.

FEATURED

Blog Posts

Need more information?

Visit our medical/pharmaceutical website at wound.doxyva.com for our FDA-approved (Rx) product line or send us a message via the below form and tell us what you are looking for.

D'OXYVA | Cardiovascular, Diabetes Care, Pain Reliever in CA.